Sophiris Bio Inc. is a late-stage, clinical biopharmaceutical company developing topsalysin (PRX302) for the treatment of patients with urological diseases. Topsalysin, a first-in-class, pore-forming protein, is a highly potent ablative agent that is selective and targeted in that it is only activated by enzymatically active PSA which is found in high concentrations around prostate tumor cells and in the transition zone of the prostate. Topsalysin has completed two Phase 2 clinical trials for the focal treatment of localized prostate cancer as well as one Phase 3 clinical trial for the treatment of the lower urinary tract symptoms of benign prostatic hyperplasia (BPH). More than 450 patients have received topsalysin, which continues to appear to be safe and well tolerated.